Cargando…
Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical mod...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072497/ https://www.ncbi.nlm.nih.gov/pubmed/32041116 http://dx.doi.org/10.3390/cancers12020370 |
_version_ | 1783506420407205888 |
---|---|
author | Fonnes, Tina Strand, Elin Fasmer, Kristine E. Berg, Hege F. Espedal, Heidi Sortland, Kristina Stefansson, Ingunn Bjørge, Line Haldorsen, Ingfrid S. Krakstad, Camilla McCormack, Emmet |
author_facet | Fonnes, Tina Strand, Elin Fasmer, Kristine E. Berg, Hege F. Espedal, Heidi Sortland, Kristina Stefansson, Ingunn Bjørge, Line Haldorsen, Ingfrid S. Krakstad, Camilla McCormack, Emmet |
author_sort | Fonnes, Tina |
collection | PubMed |
description | Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by the lack of appropriate imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging modality for visualization of orthotopic endometrial carcinoma PDX. Application of this near-infrared probe (EpCAM-AF680) enabled both spatio-temporal visualization of development and longitudinal therapy monitoring of orthotopic PDX. Notably, EpCAM-AF680 facilitated imaging of multiple PDX models representing different subtypes of the disease. Thus, the combined implementation of EpCAM-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform for identification and validation of new targeted therapies and corresponding response predicting markers for endometrial carcinoma. |
format | Online Article Text |
id | pubmed-7072497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70724972020-03-19 Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models Fonnes, Tina Strand, Elin Fasmer, Kristine E. Berg, Hege F. Espedal, Heidi Sortland, Kristina Stefansson, Ingunn Bjørge, Line Haldorsen, Ingfrid S. Krakstad, Camilla McCormack, Emmet Cancers (Basel) Article Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by the lack of appropriate imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging modality for visualization of orthotopic endometrial carcinoma PDX. Application of this near-infrared probe (EpCAM-AF680) enabled both spatio-temporal visualization of development and longitudinal therapy monitoring of orthotopic PDX. Notably, EpCAM-AF680 facilitated imaging of multiple PDX models representing different subtypes of the disease. Thus, the combined implementation of EpCAM-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform for identification and validation of new targeted therapies and corresponding response predicting markers for endometrial carcinoma. MDPI 2020-02-06 /pmc/articles/PMC7072497/ /pubmed/32041116 http://dx.doi.org/10.3390/cancers12020370 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fonnes, Tina Strand, Elin Fasmer, Kristine E. Berg, Hege F. Espedal, Heidi Sortland, Kristina Stefansson, Ingunn Bjørge, Line Haldorsen, Ingfrid S. Krakstad, Camilla McCormack, Emmet Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models |
title | Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models |
title_full | Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models |
title_fullStr | Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models |
title_full_unstemmed | Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models |
title_short | Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models |
title_sort | near-infrared fluorescent imaging for monitoring of treatment response in endometrial carcinoma patient-derived xenograft models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072497/ https://www.ncbi.nlm.nih.gov/pubmed/32041116 http://dx.doi.org/10.3390/cancers12020370 |
work_keys_str_mv | AT fonnestina nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT strandelin nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT fasmerkristinee nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT berghegef nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT espedalheidi nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT sortlandkristina nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT stefanssoningunn nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT bjørgeline nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT haldorseningfrids nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT krakstadcamilla nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels AT mccormackemmet nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels |